UBS has given Carl Zeiss Meditec a "Neutral" rating and set a price target of 65 euros. Analyst Graham Doyle has expressed doubt about the European medical technology sector, which has underperformed the overall market this year.

Doyle's sales and earnings forecasts for 2025 are lower than the consensus estimates for 10 out of the 17 stocks he covers in the industry.

As of the latest trading data, Carl Zeiss Meditec shares are priced at 57.85 euros, showing a slight increase of 0.26% from the previous day. The stock has experienced price fluctuations across different trading venues, ranging from 57.40 euros in Hanover to 57.90 euros in Munich. The stock's year-to-date high is 123.50 euros, while the low is 54.45 euros.